ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.91 CNY | +2.83% |
|
-0.40% | +39.87% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,591 | 7,097 | 7,477 | 10,458 | - | - |
| Enterprise Value (EV) 1 | 3,591 | 7,097 | 7,477 | 10,458 | 10,458 | 10,458 |
| P/E ratio | 40.8 x | 39.7 x | 19.4 x | 19.1 x | 15.7 x | 12.9 x |
| Yield | - | - | 4.22% | 4.23% | 5.16% | 6.3% |
| Capitalization / Revenue | - | - | 3.85 x | 3.98 x | 3.24 x | 2.58 x |
| EV / Revenue | - | - | 3.85 x | 3.98 x | 3.24 x | 2.58 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 2.74 x | 3.44 x | 3.18 x | 2.92 x |
| Nbr of stocks (in thousands) | 608,625 | 608,625 | 701,387 | 701,387 | - | - |
| Reference price 2 | 5.900 | 11.66 | 10.66 | 14.91 | 14.91 | 14.91 |
| Announcement Date | 3/9/21 | 3/9/22 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1,942 | 2,629 | 3,232 | 4,056 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | 448.7 | 640 | 775 | 945 |
| Operating Margin | - | - | - | 23.1% | 24.34% | 23.98% | 23.3% |
| Earnings before Tax (EBT) 1 | - | - | 3,409 | 446.6 | 634 | 769 | 939 |
| Net income 1 | 87.96 | 178.7 | 2,917 | 382.9 | 547 | 664 | 811 |
| Net margin | - | - | - | 19.71% | 20.81% | 20.54% | 20% |
| EPS 2 | 0.1445 | 0.2937 | - | 0.5500 | 0.7800 | 0.9500 | 1.160 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.4500 | 0.6300 | 0.7700 | 0.9400 |
| Announcement Date | 3/9/21 | 3/9/22 | 3/14/23 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | 13.8% | 17.9% | 20.2% | 22.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | 13.8% | 14.8% | 15.8% |
| Assets 1 | - | - | - | - | 3,964 | 4,486 | 5,133 |
| Book Value Per Share 2 | - | - | - | 3.890 | 4.340 | 4.690 | 5.110 |
| Cash Flow per Share 2 | - | - | - | 0.4100 | 0.9500 | 0.9900 | 1.160 |
| Capex 1 | - | - | - | 129 | 17 | 62 | 42 |
| Capex / Sales | - | - | - | 6.66% | 0.65% | 1.92% | 1.04% |
| Announcement Date | 3/9/21 | 3/9/22 | 3/14/23 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.91
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.87% | 1.44B | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.18B | |
| +3.98% | 3.16B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 300181 Stock
- Financials Zhejiang Jolly Pharmaceutical Co.,LTD
